Disclosed herein are compounds for treating conditions related to oxidative stress/damage among other causes, with pharmaceutically accepted salts hydrate, solvate, optical isomer, or combination thereof, comprising lipophilic cation moieties linked to heterocyclics compounds of formula (I) and formula (8);

##STR00001##

wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, and R.sub.5 may be selected from the group consisting of

##STR00002##

wherein X, Y, and Z are selected from the group consisting of H, methyl, ethyl, propyl, butyl, substituted or unsubstituted aryl, and heteroaryls; n is an integer selected from 0-18, and E is a phosphorous or nitrogen atom.

It is an object of the present invention to provide a novel medicament for preventing and/or treating ophthalmologic diseases caused by ocular angiogenesis. According to the present invention, provided is a medicament for preventing and/or treating ophthalmologic diseases caused by ocular angiogenesis, which comprises, as an active ingredient, a pyrazolone derivative such as 3-methyl-1-phenyl-2-pyrazolin-5-one, or a physiologically acceptable salt thereof, or a hydrate thereof or a solvate thereof.

It is an object of the present invention to provide a novel medicament for preventing and/or treating ophthalmologic diseases caused by ocular angiogenesis. According to the present invention, provided is a medicament for preventing and/or treating ophthalmologic diseases caused by ocular angiogenesis, which comprises, as an active ingredient, a pyrazolone derivative such as 3-methyl-1-phenyl-2-pyrazolin-5-one, or a physiologically acceptable salt thereof, or a hydrate thereof or a solvate thereof.

The present invention provides a compound having a lysine-specific demethylase 1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for cancer, and central nervous system diseases, and the like. The present invention relates to a compound represented by the formula ##STR00001##
wherein A is a hydrocarbon group or heterocyclic group optionally having substituent(s); R is H, a hydrocarbon group or heterocyclic group optionally having substituent(s); A and R are optionally bonded to each other to form a ring optionally having substituent(s); Q.sup.1, Q.sup.2, Q.sup.3 and Q.sup.4 are each a hydrogen atom or a substituent; Q.sup.1 and Q.sup.2, and Q.sup.3 and Q.sup.4, are each optionally bonded to each other to form a ring optionally having substituent(s); X is H, an acyclic hydrocarbon group or saturated cyclic group optionally having substituent(s); Y.sup.1, Y.sup.2 and Y.sup.3 are each H, a hydrocarbon group or heterocyclic group optionally having substituent(s); X and Y.sup.1, and Y.sup.1 and Y.sup.2, are each optionally bonded to each other to form a ring optionally having substituent(s); and Z.sup.1, Z.sup.2 and Z.sup.3 are each H or a substituent, or a salt thereof.

The present invention provides a compound having a lysine-specific demethylase 1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for cancer, and central nervous system diseases, and the like. The present invention relates to a compound represented by the formula ##STR00001##
wherein A is a hydrocarbon group or heterocyclic group optionally having substituent(s); R is H, a hydrocarbon group or heterocyclic group optionally having substituent(s); A and R are optionally bonded to each other to form a ring optionally having substituent(s); Q.sup.1, Q.sup.2, Q.sup.3 and Q.sup.4 are each a hydrogen atom or a substituent; Q.sup.1 and Q.sup.2, and Q.sup.3 and Q.sup.4, are each optionally bonded to each other to form a ring optionally having substituent(s); X is H, an acyclic hydrocarbon group or saturated cyclic group optionally having substituent(s); Y.sup.1, Y.sup.2 and Y.sup.3 are each H, a hydrocarbon group or heterocyclic group optionally having substituent(s); X and Y.sup.1, and Y.sup.1 and Y.sup.2, are each optionally bonded to each other to form a ring optionally having substituent(s); and Z.sup.1, Z.sup.2 and Z.sup.3 are each H or a substituent, or a salt thereof.

A plastic container has superior storage stability for pharmaceutical ingredients exhibiting a high affinity to plastic and can be mass-produced at low cost. The container has a bag body formed into a bag shape by a sheet member with a storage part on the inside thereof, and a tubular port member attached to the bag body, wherein one end of the tubular port member communicates with the storage part and an opening part of the other end is exposed outside of the bag body. The sheet member is formed from two or more layers including a base resin layer and an innermost layer formed from an amorphous polymer, as a main component, formed by polymerizing at least one type of olefin monomer, having a cyclic hydrocarbon skeleton, and the port member is formed from a resin having a crystalline polyolefin having no cyclic hydrocarbon skeleton, as a main component.

A plastic container has superior storage stability for pharmaceutical ingredients exhibiting a high affinity to plastic and can be mass-produced at low cost. The container has a bag body formed into a bag shape by a sheet member with a storage part on the inside thereof, and a tubular port member attached to the bag body, wherein one end of the tubular port member communicates with the storage part and an opening part of the other end is exposed outside of the bag body. The sheet member is formed from two or more layers including a base resin layer and an innermost layer formed from an amorphous polymer, as a main component, formed by polymerizing at least one type of olefin monomer, having a cyclic hydrocarbon skeleton, and the port member is formed from a resin having a crystalline polyolefin having no cyclic hydrocarbon skeleton, as a main component.

The present embodiments relate to compounds with physiological effects, such as the activation of hematopoietic growth factor receptors. The present embodiments also relate to use of the compounds to treat a variety of conditions, diseases and ailments such as hematopoietic conditions and disorders.

The present embodiments relate to compounds with physiological effects, such as the activation of hematopoietic growth factor receptors. The present embodiments also relate to use of the compounds to treat a variety of conditions, diseases and ailments such as hematopoietic conditions and disorders.

The present invention relates to the design and synthesis of a class of novel chiral phosphine ligand, 1,2-bis(diphenylphosphinoalkylamido)-1,2-disubstituted ethane, and use in asymmetric catalytic reactions, such as asymmetric catalytic synthesis of pyrazoline-5-one with a chiral quaternary carbon center, i.e., highly enantioselective synthesis of 3-methyl-4-benzyl-4-(2-butyl-2,3-butadienyl)pyrazoline-5-one by using 3-methyl-4-benzylpyrazoline-5-one and benzyl (2-butyl-2,3-butadienyl) carbonate with tris(dibenzylideneacetone)dipalladium-chloroform adduct and this novel ligand as catalysts. The ligand designed by this present invention has the following advantages: the structure is novel, the synthesis and enlarge are simple, the enantioselective control effect in the practical reaction is excellent, which has a broad application prospect in chiral catalysis.